Potential TGF-β-related treatment-emergent skin adverse events occurred in 6 patients (7.2%; Table 3 and Supplementary Table SA.3); the lesions were well managed by surgical excision, which is the standard of care,34 and 1 patient received topical steroid treatment for keratoacanthoma and actinic keratosis. This evidence concerns the gene TGFB1 and keratoacanthoma.